Elastic compression stockings for prevention of the post-thrombotic syndrome in patients with and without residual vein thrombosis and/or popliteal valve reflux

Prandoni, Paolo; Lensing, Anthonie W. A.; Prins, Martin H.; Villalta, Sabina; Pesavento, Raffaele; Tormene, Daniela; Noventa, Franco; Palareti, Gualtiero

doi:10.3324/haematol.2021.279680

Cited by 14 publications

(9 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Using predefined criteria, patients were classified as those who used proper stockings for at least 70% of daily time for at least one year after the thrombotic episode ('stockings' group), and those who did not ('no stockings' group). 27 The two groups were virtually comparable in terms of baseline characteristics, risk factors of venous thrombosis and risk factors of PTS. The findings were interesting.…”

Section: Elastic Compression Stockingsmentioning

confidence: 89%

See 1 more Smart Citation

New perspectives for prevention of the post-thrombotic syndrome

Prandoni¹

2022

Bleed Thromb Vascul Biol

Self Cite

View full text Add to dashboard Cite

While on conventional anticoagulation, up to 50% of patients with one or more episodes of proximal deep vein thrombosis (DVT) can develop post-thrombotic (PTS) manifestations. The potential strategies for PTS prevention are the treatment of acute DVT with catheter-directed thrombolysis (CDT), the use of elastic compression stockings (ECS) and that of the direct oral anticoagulants (DOAC) in place of vitamin K antagonists (VKA) for the initial and long-term treatment of DVT. Based on the results of three randomized clinical trials, CDT cannot be recommended on a routine basis because of its invasiveness, the associated risk of major bleedings and the uncertainty about its efficacy. According to the results of a placebo-controlled randomized clinical trial, ECS are no longer recommended for PTS prevention on a routine basis. However, based on the results of a recent subanalysis of a prospective cohort study, patients with residual vein thrombosis and/or popliteal valve reflux at three months are likely to benefit from ECS for at least six months. Finally, following the demonstration that the inadequacy of VKA therapy plays a key role in the PTS development, several retrospective and prospective studies have shown that the use of DOACs for the initial and long-term treatment of DVT in place of VKAs reduces the risk of PTS by approximately 50%. In conclusion, the availability of DOACs and the potential of ECS in selected patients with proximal DVT are expected to play a key role for decreasing the rate and the severity of PTS in the forthcoming years.

show abstract

Section: Elastic Compression Stockingsmentioning

confidence: 89%

“…Of the two vascular abnormalities, RVT was the one that impacted the study results most. 27 Accordingly, the ultrasound detection of RVT (especially if associated with PVR) three months after an acute proximal DVT has the potential to identify patients at a higher risk of developing PTS and of benefiting from ECS.…”

Section: Elastic Compression Stockingsmentioning

confidence: 99%

New perspectives for prevention of the post-thrombotic syndrome

Prandoni¹

2022

Bleed Thromb Vascul Biol

Self Cite

View full text Add to dashboard Cite

show abstract

“…In the past 30 years, some large randomized clinical trials have shown that the main methods to prevent and treat AMI caused by venous thromboembolism include Catheter-directed thrombolysis and endovascular treatment ( 28 , 29 ), which can clear the disease to a certain extent, greatly reduce the burden of thrombosis, protect vascular and valve functions, and thus reduce the incidence of recurrence of myocardial infarction. However, in actual clinical applications ( 30 ), because there are very strict indications and contraindications for thrombolysis or endovascular therapy in patients with deep vein thrombosis (DVT), especially in patients with diabetes, while AE device therapy is non-invasive and convenient, a certain degree of compression can ameliorate limb pain and swelling in DVT ideally, thus greatly improving the compliance of patients, which can allow treatment alongside daily activities as well.…”

Section: Discussionmentioning

confidence: 99%

Anti-embolism devices therapy to improve the ICU mortality rate of patients with acute myocardial infarction and type II diabetes mellitus

Huang

Zhang

et al. 2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

BackgroundAnti-Embolism (AE) devices therapy is an additional antithrombotic treatment that is effective in many venous diseases, but the correlations between this medical compression therapy and cardiovascular arterial disease or comorbid diabetes mellitus (DM) are still controversial. In this study we investigated the association between compression therapy and intensive care unit (ICU) mortality in patients with a first acute myocardial infarction (AMI) diagnosis complicated with type II DM.MethodsThis retrospective cohort study analyzed all patients with AMI and type II DM in the Medical Information Mart for Intensive Care-IV database. We extracted the demographics, vital signs, laboratory test results, comorbidities, and scoring system results of patients from the first 24 h after ICU admission. The outcomes of this study were 28-day mortality and ICU mortality. Analyses included Kaplan–Meier survival analysis, Cox proportional-hazards regression, and subgroup analysis.ResultsThe study included 985 eligible patients with AMI and type II DM, of who 293 and 692 were enrolled into the no-AE device therapy and AE device therapy groups, respectively. In the multivariate analysis, compared with no-AE device therapy, AE device therapy was a significant predictor of ICU mortality (HR = 0.48, 95% CI = 0.24–0.96, P = 0.039) and 28-day mortality (HR = 0.50, 95% CI = 0.27–0.90, P = 0.021). In addition to age, gender and coronary artery bypass grafting surgery, there were no significant interactions of AE device therapy and other related risk factors with ICU mortality and 28-day mortality in the subgroup analysis.ConclusionsSimple-AE-device therapy was associated with reduced risks of ICU mortality and 28-day mortality, as well as an improvement in the benefit on in-hospital survival in patients with AMI complicated with type II DM.

show abstract

“…Another extremely debated topic regards DVT and PTS, where doubtful evidence still exists on the utility, kind and duration of the compression device and regime [ 1 , 4 , 10 , 13 ]. In fact, after the controversial SOX trial [ 14 ], which questioned the usefulness of MCS at reducing the incidence of PTS following an acute DVT, a few well-conducted studies and one Cochrane review [ 15 , 16 , 17 ] have been published on this topic. Overall, they re-confirmed the value of compression garments to reduce PTS in limbs affected by DVT, but likely on an individualised basis.…”

Section: Phlebologymentioning

confidence: 99%